A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.

Trial Profile

A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 22 Jun 2019 to 15 Dec 2019.
    • 03 Jan 2017 Planned number of patients changed from 48 to 75.
    • 19 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top